Recurrent ovarian steroid cell tumour not otherwise specified: A case report

Baharudin, Azmaniza; Mohammad, M. S. Dewan Muthu; Abdullah, Munirah; Aliyas, Ismail; Noor, Mohd Rushdan Mohd; Yazid, Mohd Nazri; Yuan, Victor Chin Jian; Jamil, Amilia Afzan Mohd

doi:10.1002/ccr3.4414

Cited by 3 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adjuvant chemotherapy using etoposide, bleomycin and cisplatin are tried. 9 GnRH agonists are used in case of recurrent tumors with careful follow up of sex hormone levels along with clinical surveillance. 9 If the patiens had features of hyperandrogenism or oestrogenic features initially, postoperative follow up with sex hormone levels are required.…”

Section: Discussionmentioning

confidence: 99%

Rare ovarian tumor in post hysterectomized status: case report

Manikkam

2023

Int J Community Med Public Health

View full text Add to dashboard Cite

Ovarian tumors are known for their silent nature, non-availability of definitive screening methods and varied clinico pathological variations. Conservation of normal looking ovaries macroscopically during hysterectomy is recommended to benefit the future health of the woman. Still the development of new issues related to ovaries need to be counseled to the patient and stringent vigilance by the clinician is mandatory. Steroid cell tumor is rare ovarian tumor and histopathology is the gold standard for diagnosis. Any patient with high testosterone levels should be investigated meticulously to define the origin adrenal/ovarian with an awareness about this rare entity with malignant potential. Lifetime follow up of the ovaries in women are crucial at all ages. Here we report a case of rare ovarian tumor in post hysterectomized patient.

show abstract

Section: Discussionmentioning

confidence: 99%

Rare ovarian tumor in post hysterectomized status: case report

Manikkam

2023

Int J Community Med Public Health

View full text Add to dashboard Cite

show abstract

“…According to previous studies, serum estrogen levels are low in postmenopausal women with CKD treated with hemodialysis [ 7 ]. Such hormonal imbalance in patients with CKD causes bleeding in the endometrium, but there may also be an imbalance due to hormones secreted by tumors [ 2 ]. This patient had an incidental ovarian steroid cell tumor that produced hormones.…”

Section: Discussionmentioning

confidence: 99%

“…Precocious puberty can also occur in children. In adults, virilizing signs such as hoarseness of voice, hirsutism, and amenorrhea have been reported [ 2 ]. In this case, signs of virilization including acne, hirsutism, and male pattern alopecia were not identified.…”

Section: Discussionmentioning

confidence: 99%

“…In postmenopausal women, hematometra is commonly associated with cervical stenosis due to senile atrophy, radiotherapy, or neoplastic lesions involving the uterus [ 1 ]. Ovarian steroid cell tumors are a rare subtype of hormone-secreting tumors that account for approximately 0.1% of all ovarian tumors [ 2 ]. Here, we report a case of hematometra in a postmenopausal woman with high estrogen levels who was later confirmed to have a steroid cell tumor.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hematometra Due to Cervical Stenosis in a Postmenopausal Woman with Incidental Ovarian Steroid Cell Tumor: A Case Report

2022

View full text Add to dashboard Cite

Vaginal bleeding is reported among 4%–11% of postmenopausal women. Hematometra is commonly associated with cervical stenosis due to senile atrophy, radiotherapy, or a uterine neoplastic lesion in women of postmenopausal age. Ovarian steroid cell tumor is a rare hormone-secreting tumor subtype accounting for approximately 0.1% of all ovarian tumors. Here we report a case of hematometra in a postmenopausal woman with high estrogen levels who was later diagnosed with a steroid cell tumor.

show abstract

“…Subsequently, four courses of bleomycin+etoposide+cisplatin (BEP), followed by six courses of etoposide+cisplatin (EP), were administered 19…”

Section: Treatmentmentioning

confidence: 99%

Somatic gene mutations in malignant steroid cell tumours and response to multiple treatments

Nakanishi

Fukagawa²,

Yamada³

et al. 2022

BMJ Case Rep

View full text Add to dashboard Cite

Malignant ovarian steroid cell tumours are a rare subgroup of sex cord-stromal tumours. There are no systematic reviews on the associated treatments, and little is known about their genomic profile. We describe a case of a pelvic malignant ovarian steroid cell tumour in a premenopausal woman in her 40s. She received cytoreductive surgery and six cycles of paclitaxel+carboplatin+bevacizumab. After recurrence, the tumour was surgically removed again, followed by radiation and hormone blockade therapy. Complete remission was achieved after treatment with bleomycin, etoposide and cisplatin. She remained in a platinum-sensitive relapse state and subsequently received maintenance therapy with olaparib. Since the tumour was initially refractory to treatment, tissue specimens were screened for gene mutations using a next-generation sequencing oncology panel and a somatic variant detection system, which revealed somatic gene mutations in ARID1A, PIK3CA, TERT and ATM, some of which are involved in DNA repair.

show abstract

Recurrent ovarian steroid cell tumour not otherwise specified: A case report

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cited by 3 publications

References 21 publications

Rare ovarian tumor in post hysterectomized status: case report

Rare ovarian tumor in post hysterectomized status: case report

Hematometra Due to Cervical Stenosis in a Postmenopausal Woman with Incidental Ovarian Steroid Cell Tumor: A Case Report

Somatic gene mutations in malignant steroid cell tumours and response to multiple treatments

Contact Info

Product

Resources

About